Last reviewed · How we verify
NCT03544489: E-ICD
Effectiveness of Exercise After an ICD
Phase 2, PHASE3 trial testing E-ICD Intervention in Heart Arrest in 210 participants. Currently enrolling.
14 September 2029
Quick facts
| Lead sponsor | University of Washington |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 210 |
| Start date | 1 May 2025 |
| Primary completion | 14 September 2029 |
| Estimated completion | 14 September 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- E-ICD Intervention
Conditions studied
- Heart Arrest — all drugs for Heart Arrest →
- Implantable Defibrillator User — all drugs for Implantable Defibrillator User →
- Physical Activity — all drugs for Physical Activity →
Sponsor
University of Washington
Who can join
18 and older, any sex, with Heart Arrest or Implantable Defibrillator User. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will test an exercise intervention (E-ICD) following an implantable cardioverter defibrillator.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Exercise-based cardiac rehabilitation for adult patients with an implantable cardioverter defibrillator.
Nielsen KM, Zwisler AD, Taylor RS, Svendsen JH, et al · · 2019 · cited 21× · PMID 30746679 · DOI 10.1002/14651858.cd011828.pub2
Verify or expand the search:
- PubMed search for NCT03544489
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Arrest
Currently open trials in the same condition.
- NCT06159764 — National Registry of Cardioneuroablation in Recurrent Reflex Syncope · recruiting
- NCT06401707 — PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest · Phase 2 · recruiting
- NCT05321459 — Predictive Outcome in Comatose Patients · recruiting
- NCT05851391 — buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest · Phase 2 · recruiting
- NCT05173740 — Rehabilitation for Survivors of Out-of-hospital Cardiac Arrest · Phase 4 · recruiting
Other University of Washington trials
Trials by the same sponsor.
- NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
- NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
- NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
- NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03544489 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Washington
- Last refreshed: 23 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03544489.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing